Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4146731 | 0.99 | PTGS2 (0.58) | PTGS2PTGS1ESR2CA12CA1 | |
| SCHEMBL3043548 | 0.83 | PTGS2 (0.69) | PTGS2PTGS1ESR2CA12CA1 | |
| SCHEMBL27637961 | 0.83 | PTGS1 (0.41) | PTGS2PTGS1TDP1 | |
| SCHEMBL27637960 | 0.83 | PTGS1 (0.41) | PTGS2PTGS1TDP1 | |
| SCHEMBL29938771 | 0.81 | PTGS2 (0.87) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL5604980 | 0.81 | PTGS2 (0.87) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL6375235 | 0.81 | PTGS2 (0.87) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL5605782 | 0.81 | PTGS2 (0.87) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL5604953 | 0.80 | PTGS2 (0.85) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL27637962 | 0.76 | PTGS2 (0.46) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100217028-A1 | PROCESS FOR PREPARING NITROOXYALKYL SUBSTITUTED ESTERS OF CARBOXYLIC ACIDS, INTERMEDIATES USEFUL IN SAID PROCESS AND PREPARATION THEREOF | NICOX S.A. (FR) | 2010-08-26 | — | — | US | disclosed |
| US-7723382-B2 | Process for preparing nitrooxyalkyl substituted esters of carboxylic acids, intermediates useful in said process and preparation thereof | NICOX S.A. (FR) | 2010-05-25 | — | — | US | disclosed |
| US-20070112194-A1 | Process for preparing nitrooxyalkyl substituted esters of carboxylic acids, intermediates useful in said process and preparation thereof | NICOX S.A. (FR) | 2007-05-17 | — | — | US | disclosed |
| EP-1537070-A1 | PROCESS FOR PREPARING NITROOXYALKYL SUBSTITUTED ESTERS OF CARBOXYLIC ACIDS, INTERMEDIATES USEFUL IN SAID PROCESS AND PREPARATION THEREOF | Nicox S.A. (FR) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020385-A1 | PROCESS FOR PREPARING NITROOXYALKYL SUBSTITUTED ESTERS OF CARBOXYLIC ACIDS, INTERMEDIATES USEFUL IN SAID PROCESS AND PREPARATION THEREOF | NICOX S.A. (FR) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100217028-A1 | PROCESS FOR PREPARING NITROOXYALKYL SUBSTITUTED ESTERS OF CARBOXYLIC ACIDS, INTERMEDIATES USEFUL IN SAID PROCESS AND PREPARATION THEREOF | CYP2A13, CYP3A43, POR | PTGS2 1142/4885PTGS1 1667/4885ESR2 586/4885 |
| US-20070112194-A1 | Process for preparing nitrooxyalkyl substituted esters of carboxylic acids, intermediates useful in said process and preparation thereof | CYP2A13, CYP3A43, POR | PTGS2 1142/4885PTGS1 1667/4885ESR2 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.